pyrroles has been researched along with Opportunistic Infections in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| D'Haens, GR; Guo, X; Kulisek, N; Lawendy, N; Modesto, I; Mundayat, R; Ng, SC; Panaccione, R; Panés, J; Sandborn, WJ; Sands, BE; Su, C; Vranic, I | 1 |
| Chen, C; Kwok, K; Lee, EB; Liu, Y; Llamado, LJ; Luo, Y; Sugiyama, N; Tanaka, Y; Tsai, WC; Wang, L; Yamanaka, H; Yoo, HJ | 1 |
| Boland, BS; Chang, JT; Sandborn, WJ | 1 |
| Cardiel, MH; Gomez-Reino, JJ; Gul, A; Kwok, K; Lukic, T; Mortensen, E; Park, SH; Ponce de Leon, D; Riese, R; Tanaka, Y; Valdez, H; Winthrop, KL | 1 |
| Anisfeld, A; Chen, C; Chen, Y; Curtis, JR; Geier, J; Krishnaswami, S; Strengholt, S; Zhang, R | 1 |
| Charles-Schoeman, C; Cohen, SB; Curtis, JR; DeMasi, R; Geier, J; Kwok, K; Lee, EB; Mariette, X; Nash, P; Riese, R; Tanaka, Y; Thirunavukkarasu, K; Wang, L; Winthrop, KL; Wollenhaupt, J | 1 |
| Duprez, O; Gao, F; Paes, MN; Visvardis, EE; Waxman, J | 1 |
2 review(s) available for pyrroles and Opportunistic Infections
| Article | Year |
|---|---|
Update on Janus kinase antagonists in inflammatory bowel disease.
Topics: Animals; Dyslipidemias; Humans; Inflammatory Bowel Diseases; Janus Kinases; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction | 2014 |
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Immunocompromised Host; Immunosuppressive Agents; Incidence; Janus Kinase 3; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Assessment; Tuberculosis | 2016 |
1 trial(s) available for pyrroles and Opportunistic Infections
| Article | Year |
|---|---|
Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.
Topics: Colitis, Ulcerative; Herpes Zoster; Humans; Janus Kinase Inhibitors; Opportunistic Infections; Protein Kinase Inhibitors; Pyrroles; Skin Neoplasms; Treatment Outcome | 2023 |
4 other study(ies) available for pyrroles and Opportunistic Infections
| Article | Year |
|---|---|
Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data.
Topics: Adult; Arthritis, Rheumatoid; Asia; Clinical Trials as Topic; Evidence-Based Medicine; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Neoplasms; Opportunistic Infections; Piperidines; Pyrimidines; Pyrroles; Recovery of Function; Remission Induction; Risk Factors; Time Factors; Treatment Outcome | 2019 |
Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Neoplasms; Opportunistic Infections; Piperidines; Pyrimidines; Pyrroles; Risk Assessment | 2017 |
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Herpes Zoster; Humans; Immunocompromised Host; Incidence; Infections; Male; Middle Aged; Neoplasms; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Tuberculosis; Young Adult | 2017 |
Lung Aspergillosis in renal cell carcinoma patient treated with sunitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Lung Neoplasms; Male; Opportunistic Infections; Pulmonary Aspergillosis; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2012 |